Exelixis
EXEL · Nasdaq · United States
Share price · EXEL
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when EXEL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 30 Oct 2026+4.8%
- 6 Aug 2026-7.9%
- 3 Aug 2026+3.8%
Nothing announced by EXEL that day or the session before.
- 3 Jun 2026+6.3%
Nothing announced by EXEL that day or the session before.
- 8 May 2026+4.2%
Nothing announced by EXEL that day or the session before.
- 6 May 2026+9.6%
- 21 Apr 2026+5.2%
Nothing announced by EXEL that day or the session before.
- 15 Apr 2026-3.4%
Nothing announced by EXEL that day or the session before.
- 10 Mar 2026-2.5%
Nothing announced by EXEL that day or the session before.
- 2 Mar 2026-6.9%
Nothing announced by EXEL that day or the session before.
Share of unusual movement by asset
For each asset, the share of EXEL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(5 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | MET / VEGFR / AXL / RET (multi-kinase)Small molecule | Non-Small Cell Lung CancerRenal Cell CarcinomaHepatocellular CarcinomaProstate Cancer Clear Cell Renal Cell Carcinoma | |
| Approved | MEK1/2Small molecule | Melanoma | |
| Phase 3 | VEGFR2; MET; AXL; MER; TYRO3Small molecule | Non-Small Cell Lung CancerRenal Cell CarcinomaColorectal Cancer Clear Cell Renal Cell Carcinoma | |
| Phase 1 | SIRPα (Signal regulatory protein alpha)Monoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 1 | 5T4 (trophoblast glycoprotein, TPBG)Antibody–drug conjugate | Non-Small Cell Lung Cancer |
Upcoming events
(11 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (1)
June 2027 (1)
What to watch
2028 (5)
February 2028 (2)
June 2028 (1)
What to watch
July 2028 (1)
August 2028 (1)
What to watch
2029 (1)
June 2029 (1)
What to watch
2030 (2)
April 2030 (1)
What to watch
May 2030 (1)
What to watch
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q4 | $659M | $209M | $305M+ $587M short-term inv. | —$280M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $629M | $212M | $281M+ $558M short-term inv. | —$308M operating cash flow | report ↗ |
| 2026-Q2 | $611M | $200M | $226M+ $551M short-term inv. | —$252M operating cash flow | report ↗ |
| 2025-Q4 | $598M | $199M | $376M+ $612M short-term inv. | —$290M operating cash flow | report ↗ |
| 2025-Q3 | $568M | $200M | $164M+ $627M short-term inv. | —$49M operating cash flow | report ↗ |
| 2025-Q2 | $555M | $212M | $184M+ $848M short-term inv. | —$211M operating cash flow | report ↗ |
| 2024-Q3 | $540M | $223M | $258M+ $931M short-term inv. | —$271M operating cash flow | report ↗ |
| 2024-Q2 | $637M | $211M | $198M+ $804M short-term inv. | —$120M operating cash flow | report ↗ |
| 2024-Q1 | $425M | $228M | $260M+ $704M short-term inv. | —$69M operating cash flow | report ↗ |
| 2023-Q3 | $472M | $333M | $397M+ $707M short-term inv. | —$117M operating cash flow | report ↗ |
| 2023-Q2 | $470M | $233M | $464M+ $802M short-term inv. | —$121M operating cash flow | report ↗ |
| 2023-Q1 | $409M | $234M | $542M+ $773M short-term inv. | —$84M operating cash flow | report ↗ |
| 2022-Q3 | $419M | $199M | $638M+ $908M short-term inv. | —$31M operating cash flow | report ↗ |
| 2022-Q2 | $356M | $157M | $737M+ $847M short-term inv. | —$148M operating cash flow | report ↗ |
| 2021-Q4 | $328M | $163M | $598M+ $835M short-term inv. | —$83M operating cash flow | report ↗ |
| 2021-Q3 | $385M | $149M | $539M+ $854M short-term inv. | —$182M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-FY | $2.3B | $825M | $482M+ $577M short-term inv. | —$884M operating cash flow | report ↗ |
For fiscal 2025, Exelixis reported revenue of $2,320.13M, up 7.0% YoY. R&D spend was $825M, down 9.4% YoY from $910.41M, and cash and equivalents stood at $482.49M. Net income or loss was not disclosed in the provided figures, nor was quarterly net burn.
Operationally, Exelixis noted its ninth consecutive year of annual profitability, with cabozantinib-related net product revenue growth of approximately 17% YoY and royalty growth of approximately 7% YoY. Its lead pipeline asset, zanzalintinib, was under FDA review for certain forms of colorectal cancer and in late-stage development for other indications. CABOMETYX received U.S. approval in March 2025 and EEA/U.K. approvals later in 2025 for previously treated well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors. Early-stage pipeline candidates include XL309, XB010, XB628, and XB371.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $2.2B | $910M | $217M+ $894M short-term inv. | —$700M operating cash flow | report ↗ |
| 2023-FY | $1.8B | $1.0B | $263M+ $732M short-term inv. | —$333M operating cash flow | report ↗ |
| 2022-FY | $1.6B | $892M | $503M+ $807M short-term inv. | —$363M operating cash flow | report ↗ |
| 2021-FY | $988M | $548M | $321M+ $887M short-term inv. | —$209M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($1.2M), 25 sales ($32.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-10 | Beckerle Mary C · director | Open-market sale | 9,812 | $53.66 | $527K | Form 4 |
| 2026-06-01 | Eckhardt Sue Gail · director | Open-market sale | 9,812 | $50.14 | $492K | Form 4 |
| 2026-06-01 | WYSZOMIERSKI JACK L · director | Open-market sale | 3,925 | $50.55 | $198K | Form 4 |
| 2026-05-27 | JOHNSON DAVID EDWARD; Caligan Partners LP · director; director | Award / grant (derivative) | 19,133 | — | — | Form 4 |
| 2026-05-27 | POSTE GEORGE · director | Award / grant | 8,367 | — | — | Form 4 |
| 2026-05-27 | WYSZOMIERSKI JACK L · director | Award / grant | 8,367 | — | — | Form 4 |
| 2026-05-27 | Oliver Bob · director | Award / grant | 8,367 | — | — | Form 4 |
| 2026-05-27 | Beckerle Mary C · director | Award / grant | 8,367 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 691 reporting institutions held 257.4M shares ($10.5B, 105.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 30,816,309 | $1.3B |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 13,726,993 | $588.8M |
| 3 | FARALLON CAPITAL MANAGEMENT LLC | 13,111,010 | $562.3M |
| 4 | AQR CAPITAL MANAGEMENT LLC | 13,095,741 | $561.7M |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 12,085,273 | $518.3M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 11,258,984 | $482.9M |
| 7 | STATE STREET CORP | 10,298,439 | $441.7M |
| 8 | FULLER & THALER ASSET MANAGEMENT, INC. | 8,542,236 | $366.4M |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 7,795,610 | $334.4M |
| 10 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 4,834,625 | $207.4M |
| 11 | Invesco Ltd. | 4,314,381 | $185.0M |
| 12 | DIMENSIONAL FUND ADVISORS LP | 4,299,597 | $184.4M |
| 13 | MORGAN STANLEY | 4,178,236 | $179.2M |
| 14 | Nuveen, LLC | 3,782,734 | $162.2M |
| 15 | D. E. Shaw & Co., Inc. | 3,603,063 | $154.5M |